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Abstract
Background and Objective
Low molecular weight heparins (LMWHs) are small enough to pass large pore dialysis
membranes. Removal of LMWH if injected before the start of the session is possible during
high-flux dialysis and hemodiafiltration. The aim of this study was to determine the optimal
mode (place and time) of tinzaparin administration during postdilution hemodiafiltration.
Study Design, Setting, Patients
In 13 chronic hemodiafiltration patients, 3 approaches of injection were compared in a ran-
domised cross over trial: i) before the start of the session at the inlet blood line filled with
rinsing solution (IN0), ii) 5 min after the start at the inlet line filled with blood (IN5) and iii)
before the start of the session at the outlet blood line (OUT0). Anti-Xa activity, thrombin
generation, visual clotting score and reduction ratios of urea and beta2microglobulin were
measured.
Results
Anti-Xa activity was lower with IN0 compared with IN5 and OUT0, and also more thrombin
generation was observed with IN0. No differences were observed in visual clotting scores
and no clinically relevant differences were observed in solute reduction ratio. An anti-Xa of
0.3 IU/mL was discriminative for thrombin generation. Anti-Xa levels below 0.3 IU/mL at the
end of the session were associated with worse clotting scores and lower reduction ratio of
urea and beta2microglobulin.
Conclusions
Injection of tinzaparin at the inlet line before the start of postdilution hemodiafiltration is as-
sociated with loss of anticoagulant activity and can therefore not be recommended. Addi-
tionally, we found that an anti-Xa above 0.3 IU/mL at the end of the session is associated
with less clotting and higher dialysis adequacy.
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Introduction
For renal replacement strategies such as hemodialysis and hemodiafiltration, anticoagulants
are required to prevent clotting of the extracorporeal circuit. Over-anticoagulation can be asso-
ciated with hemorrhage and prolonged bleeding at the needle insertion sites. Insufficient inhi-
bition of the coagulation cascade can lead to premature interruption of the dialysis session.
More subtle under-anticoagulation could lead to clotting of some fibers with a decrease in
membrane exchange surface area eventually resulting in a reduction in dialysis efficiency.
Low molecular weight heparins (LMWH) are often preferred to unfractionated heparin [1]
because of the ease of a single injection at the start of the session; they are widely used anticoag-
ulants for hemodialysis [2]. LMWHs have mean molecular weights (MW) between 3600 and
6500 D. Therefore, especially if unbound, they can pass high-flux dialysis membranes. So when
LMWHs are administered at the inlet blood line before the lines are filled with blood, they may
disappear in the dialysate compartment. Tinzaparin is a LMWH obtained by enzymatic depo-
lymerization of unfractionated heparin. The mean MW of the chains is 6500 D.
The aim of this study was to determine the optimal mode of administration of LMWH as
anticoagulant during postdilution hemodiafiltration.
Three approaches of administration of tinzaparin were compared: i) before the start of the
session at the inlet blood line filled with rinsing solution (IN0), ii) 5 min after the start of the
session at the inlet blood line filled with blood (IN5) and iii) before the start of the session at
the outlet blood line (OUT0). Anti-Xa levels, thrombin generation, visual appreciation of clot-
ting of the circuit and dialysis performance measured as RR of a small and middle MWmole-
cule were considered.
Materials and Methods
Study design
The protocol for this trial and supporting CONSORT checklist are available as supporting in-
formation; see S1–S3 Texts. The study flow chart of this cross over randomised trial is summa-
rized in Fig 1. In each patient, three options were studied in cross over: i) administration of
tinzaparin at the inlet blood line just before the start of the blood pump (IN0), ii) administra-
tion at inlet blood line 5 minutes after the detection of blood by the blood detector (IN5) and
iii) administration at the outlet blood line just prior the start of the blood pump (OUT0). The
dose of tinzaparin remained unchanged throughout the study. The sequence of the sessions per
patient was assigned randomly. For each patient, the experimental sessions were performed
with a 1-week interval at the same dialysis day of the week, either first, second, or third session
of the week. Blood was sampled from the vascular access at the start of the session, before hepa-
rin injection and from the inlet dialyzer blood line at times 10, 30, 120, 180 and 240 min. Also
transmembrane pressure (TMP), prefilter pressure, pressure in inlet and outlet bloodline were
registered at 10, 30, 60, 90, 120, 150, 180, 210 and 240 min. Primary end-point was the anti-Xa
activity at the end of the session. Secondary end-points were: anti-Xa activity at the start, after
30, 120 and 180 min, ETP at the start and after 30, 120, 180 and 240 min, dialysis efficiency
measured as reduction ratio of urea and beta2microglobulin after 10, 180 and 240 min. Other
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secondary end-points were visual clotting scores at the end of the session and pressure mea-
surements along the circuit.
Patients
Fourteen patients treated with chronic hemodiafiltration at the Ghent University Hospital
were included in the study from september 2008 until march 2010 (Fig 1). Inclusion criteria
were chronic kidney disease stade V, older than 18 years and hematocrit above 30%. Exclusion
criteria for the study were: active bleeding, infection or malignancy, hepatic failure, thrombocy-
topenia below 120,000/μL, treatment with vitamin K antagonists, administration of heparin or
anticoagulants for other reasons than anticoagulation for dialysis, allergy towards heparin.
Thirteen chronic hemodialysis patients (8 males, 5 females, median age 74 years (69–80 inter-
quartile range)), completed the study. One patient was prematurely excluded due to an unrelat-
ed infectious adverse event. The median and interquartile range of body weight was 68 (63–
81.5) kg. The renal diagnoses were diabetic nephropathy (n = 4), renal vascular disease (n = 3),
chronic interstitial kidney disease (n = 2), and other (n = 4). As dialyis anticoagulant, tinza-
parin (Innohep, Leo Pharmaceutical Corp, Ballerup, Denmark), with median and interquartile
range of 4500 (3500–4500) IU was routinely used. Before the study, tinzaparin was injected in
the afferent blood line shortly after the start of the session. The doses had been defined prior to
the start of the study, based on the presence or absence of visible clotting of membrane and cir-
cuit and/or prolonged bleeding after dialysis.
Four patients received antiplatelet therapy, either aspirin (n = 3) and/or clopidogrel (n = 2).
Residual renal function measured as average of creatinine and urea clearance was 3.0 (0–5.2)
mL/min.
Fig 1. Study flow chart: generation of allocation sequence, enrollment and assignment was done by AD.
doi:10.1371/journal.pone.0128634.g001
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Ethics statement
Approval of the local ethics committee (Ghent University Hospital ethics committee) was ob-
tained, as well as written informed consent of all patients. The study was registered in clinical-
trials.gov as NCT00756145.
Hemodiafiltration
The hemodiafiltration treatments were performed with AK200 ULTRA S (Gambro, Lund,
Sweden) dialysis machines with BL200BD and BL208BD (Gambro, Medolla, Italy) as inlet and
outlet blood lines. As dialyzer, single use Helixone membranes (FX800, Fresenius Medical
Care, Bad Homburg, Germany) were used. No heparin was added in the rinsing solution of
the circuit.
As anticoagulant, prefilled syringes containing tinzaparin were used in the same dose as
before the study. The hemodiafiltration sessions lasted 240 minutes with the following char-
acteristics: effective blood flow 300 mL/min, dialysate flow 600 mL/min, volume controlled
postdilution hemodiafiltration with an effective convection rate of 75 mL/min.
During the sessions no other intravenous medication was administered.
At the end of the session, the circuit was rinsed by means of an online restitution program.
Sample collection
Blood samples were collected in citrated tubes (Venosafe 3.6 ml, 0.109 M buffered sodium cit-
rate, Terumo Europe, Leuven, Belgium) for measurement of anti-Xa, antithrombin and throm-
bin generation; in tubes with gel and clotting activator (VenosafeAutosep, Terumo) for CRP,
urea and beta2microglobulin and in K-EDTA tubes (BD Plymouth, UK) for hematocrit.
Hematocrit and CRP were measured immediately; serum and plasma samples for all other
determinations were kept at −80°C for further analysis.
Analytical techniques
CRP was measured through a particle enhanced immunoturbidimetric assay (CRPLX, Roche
Diagnostica, Mannheim, Germany).
Hematocrit was determined by centrifugation (Heraus Centrifuge, Labofuge 400).
Beta2microglobulin concentrations were quantified using an ELISA kit (Orgentec Diagnos-
tika GmbH, Mainz, Germany) and an EL808 Ultramicroplate Reader (Bio-Tek Instruments,
Winooski, VT, USA).
Urea was measured by a standard laboratory method on Roche Cobas 6000 chemistry ana-
lyzer (Roche Diagnostics).
Anti-Xa activity was measured by a chromogenic method (Biophen Heparin, Hyphen
BioMed, Neuville-sur-Oise, France) on a STA-C (Diagnostica Stago, Asnières, France) with de-
tection limit 0.05 IU/mL.
Analysis of antithrombin was carried out using a chromogenic method (Coamatic Anti-
thrombin, Chromogenix, Instrumentation Laboratory, Milan, Italy).
Automated measurement of thrombin generation was performed by Calibrated Automated
Thrombography (Thrombinoscope, Maastricht, The Netherlands), as reported previously [3].
Thrombin generation was triggered in platelet-poor plasma in the presence of 5 pM tissue fac-
tor and a concentration of 4 μM phospholipids. Measurements were performed in duplicate
and reported as endogenous thrombin potential (ETP), being the area under the curve of
thrombin generation over time. Values were normalized by dividing the patient sample result
by the result of a pooled plasma from 50 healthy donors analyzed in the same run.
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Other parameters
Transmembrane pressure (TMP), prefilter pressure, pressure in inlet and outlet bloodline as
well as hemoconcentration measured by blood volume sensor (BVS) were registered at 10, 30,
60, 90, 120, 150, 180, 210 and 240 min.
At the end of the session, immediately after blood restitution, visual clotting score of mem-
brane, blood lines, expansion chamber and bubble trap were rated by two unblinded investiga-
tors (AD and RP). They rated independently, followed by consensus. The clotting score of the
membrane was as follows: 0 = no clotting, 1 = a few colored fibers, 2 = less than 50% of the visi-
ble fibers colored and 3 = more than 50% of fibers colored. Clotting of blood lines, expansion
chamber and bubble trap was scored as: 0 = no clotting, 1 = discoloration, 2 = minimal clot,
3 = major clot.
Applied compression time was registered.
Calculations and statistics
Sample size was set at 14, based on feasibility. No prior data on anti-Xa activity in this setting
were available to calculate sample size.
The sequence of the sessions per patient was randomized by Quick Calcs (Graphpad soft-
ware), an online computer system which generates a random number sequence based on the
number of experimental groups. The allocation was not concealed.
Reduction ratio (RR), concentration at different time points (Ct after 10, 180 and 240 min)
versus the start of dialysis (C0) expressed in %, was calculated as:
RR ¼ 100 X ½ðC0  CtÞ=C0 ð1Þ
Concentrations of beta2microglobulin were corrected for hemoconcentration as measured
by BVS:
Ctcorrected ¼ CtX 100=ð100 BVSÞ ð2Þ
Delta TMP was calculated as the measured TMP at 240 min minus the TMP measured at 10
min. Data are expressed as median and interquartile ranges. Statistics and figures were generat-
ed with SPSS (SPSS Inc., Chicago, IL) and GraphPad Prism 4.0 (GraphPad Software, San
Diego, California). Continuous paired data were analyzed with repeated measures analysis of
variance (Friedman) followed by Wilcoxon in case of significance. Chi square test was per-
formed for categorical variables. Correlations were tested with Spearman correlation test. Re-
ceiver Operator Characteristic (ROC) analysis was applied to determine cut off values of anti-
Xa. Significance was accepted if p<0.05.
Deviation from initial protocol
Initially we intended to measure clearances for urea and beta2microglobulin as measure of dial-
ysis efficiency. This was however not feasible due to the important interference of the decrease
in bloodwaterflow due to ultrafiltration. Hence dialysis efficiency was expressed as reduction
ratio of urea and beta2microglobulin.
Primary and secondary end-points were initially ill-defined; a shift towards secondary end-
points with only one primary end-point left was made.
Patient N° 5 received his second experimental session (IN0) 2 days later than planned be-
cause of a technical problem.
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Initially we intended to have 14 patients completing the study. Due to feasibility issues we
did not replace patient N° 4 (after his exclusion from the study due to infection). So we ended
up with 13 patients completing the study.
Results
The median and interquartile range of the administered dose of tinzaparin was 66.0 (54.5–
69.8) IU/kg body weight (S1 Fig). No premature interruptions of the sessions or bleeding
occurred.
In Table 1, predialysis values of hematocrit, antithrombin and CRP are shown as well as ul-
trafiltration and substitution volumes and fistula compression times. No differences between
the 3 schedules were observed.
Coagulation parameters
Anti-Xa activity. The evolution of anti-Xa activity is displayed in Table 2 and S2 Fig Pre-
dialysis anti-Xa activity was consistently zero. The highest values were measured at 30 min,
Table 1. Predialysis hematocrit, antithrombine, CRP and applied volumes and compression times:
median and interquartile range.
IN0 IN5 OUT0
Hematocrit (%) 36 (35–39) 36 (35–39) 37 (34–38)
Antithrombin (%) 97 (92–112) 97 (86–99) 93 (86–113)
CRP (mg/L) 3 (1–7) 3 (2–6) 2 (2–11)
Ultraﬁltered volume (L) 1.65 (0.79–1.88) 1.69 (0.86–2.42) 1.39 (0.79–2.38)
Substitution volume (L) 15.8 (15.2–16.3) 15.7 (14.8–16.4) 16.1 (15.6–16.7)
Applied compression time inlet needle (min) 16 (13–18) 15 (13–16) 15 (9–18)
Applied compression time outlet needle (min) 14 (9–16) 12 (9–16) 14 (7–14)
Abbreviations: IN0: tinzaparin injection before the start of the session at the inlet blood line; IN5: injection 5
min after the start of the session at the inlet blood line and OUT0: injection before the start of the session at
the outlet blood line; C Reactive Protein (CRP.)
Comparison between schedules: no signiﬁcant differences.
doi:10.1371/journal.pone.0128634.t001
Table 2. Anti-Xa activity: median and interquartile range.
IN0 IN5 OUT0 Comparison between schedules: p
Pre 0 (0–0) 0 (0–0) 0 (0–0)
30 min 0.95 (0.88–1.27) 1.13 (1.06–1.33) 1.12 (0.89–1.37) IN0 vs IN5:0.01IN0 vs OUT0:0.094 IN5
vs OUT0:0.37
120 min 0.65 (0.46–0.97) 0.77 (0.56–0.97) 0.74 (0.57–1.07) IN0 vs IN5:<0.001IN0 vs
OUT0:0.003IN5 vs OUT0:0.63
180 min 0.34 (0.25–0.75) 0.50 (0.34–0.78) 0.47 (0.29–0.85) IN0 vs IN5:0.01IN0 vs OUT0:0.01IN5
vs OUT0:0.34
240 min 0.14 (0.09–0.45) 0.24 (0.17–0.60) 0.25 (0.15–0.64) IN0 vs IN5:<0.001IN0 vs OUT0:
<0.001IN5 vs OUT0:0.45
Comparison between
time points: p
Between all time
points: 0.001
Pre vs 240 min: 0.002Between all
other time points: 0.001
Between all time
points: 0.001
Abbreviations: IN0: tinzaparin injection before the start of the session at the inlet blood line; IN5: injection 5 min after the start of the session at the inlet
blood line and OUT0: injection before the start of the session at the outlet blood line.
doi:10.1371/journal.pone.0128634.t002
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followed by a gradual decrease. When comparing the different schedules, the lowest anti-Xa ac-
tivity was measured during the sessions with administration of tinzaparin at the inlet blood
line before the start (IN0). No differences in anti-Xa levels were observed between IN5 and
OUT0.
Endogenous thrombin potential (ETP). The evolution of ETP is presented in Table 3.
ETP decreased from normal values predialysis to zero at 30 and 120 min. After 180 and 240
min ETP was again detected in 8 and 21 out of 39 sessions, respectively. When tinzaparin was
administered at the inlet line before the start (IN0), a higher ETP was observed compared to
the sessions where tinzaparin was administered after 5 min (IN5) or at the outlet line (OUT0).
Visual clotting scores. Visual clotting score of blood lines was consistently scored 0 for all
sessions. Visual clotting scores of membrane, expansion chamber and bubble trap were not dif-
ferent in the three administration schedules (S3 Fig).
Relationship between clotting parameters. The relation between ETP and anti-Xa activi-
ty can be appreciated from Fig 2. When anti-Xa activity is zero, ETP is present. As soon as
anti-Xa rises above 0.3 IU/mL, ETP is undetectable. With an anti-Xa value below 0.3 IU/mL, a
gradual increase in ETP is observed with decreasing anti-Xa.
Using ROC analysis, an anti-Xa activity of 0.3 IU/mL was able to discriminate for detectable
ETP with a sensitivity and specificity of 0.953 and 0.985, respectively (area under the ROC
curve of 0.996 with 95% confidence interval: 0.99–1.00).
When evaluating the visual clotting score of the membrane, bubble trap and expansion
chamber in function of anti-Xa activity at the end of the session, severe clotting (score 3) was
not observed in patients with residual anti-Xa activity above 0.3 IU/mL at the end of the session
(S4 Fig). When comparing visual clotting scores in patients with a residual anti-Xa activity
below versus above 0.3 IU/mL, a significantly higher clotting score of bubble trap and expan-
sion chamber was observed in those with anti-Xa below 0.3 IU/mL (p<0.001 and p = 0.012, re-
spectively). When comparing visual clotting scores in patients with or without ETP at 240 min,
also a higher clotting score of bubble trap and expansion chamber was observed in patients
with ETP (p<0.001 and p = 0.014, respectively).
Table 3. Endogenous Thrombin Potential (ETP): median and interquartile range.
IN0 IN5 OUT0 Comparison between
schedules: p
Pre 0.96 (0.84–1.16) 0.97 (0.88–1.12) 0.97 (0.86–1.14) IN0 vs IN5:0.19IN0 vs
OUT0:0.94IN5 vs
OUT0:0.50
30 min 0 (0–0) 0 (0–0) 0 (0–0)
120 min 0 (0–0) 0 (0–0) 0 (0–0)
180 min 0 (0–0.07) 0 (0–0) 0 (0–0) IN0 vs IN5:0.062IN0 vs
OUT0:0.19IN5 vs
OUT0:1
240 min 0.39 (0–0.60) 0.06 (0–0.17) 0.01 (0–0.09) IN0 vs IN5:0.031IN0 vs
OUT0:0.039IN5 vs
OUT0:0.55
Comparison
between time
points: p
Pre vs all time points: <0.00130
and 120 min vs 180 min: 0.04330
and 120 min vs 240 min:
0.018180 vs 240 min: 0.016
Pre vs all time points: <0.00130
and 120 min vs 180 min: 0.1830
and 120 min vs 240 min:
0.018180 vs 240 min: 0.016
Pre vs all time points: <0.00130
and 120 min vs 180 min: 0.3230
and 120 min vs 240 min:
0.018180 vs 240 min: 0.016
Abbreviations: IN0: tinzaparin injection before the start of the session at the inlet blood line; IN5: injection 5 min after the start of the session at the inlet
blood line and OUT0: injection before the start of the session at the outlet blood line.
doi:10.1371/journal.pone.0128634.t003
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Pressure measurement
Transmembrane pressure (TMP). TMP increased during the session from 53 (48–57)
mmHg at 10 min to 85 (78–104) at 240 min (p<0.001) for IN0, from 52 (47–56) to 79 (70–99)
for IN5 (p<0.001) and from 54 (48–57) to 90 (77–103) mmHg for OUT0 (p<0.001). No differ-
ences were observed between the three groups, neither at 10 nor at 240 min.
The increase in TMP at the end of the session expressed as delta TMP was not different be-
tween the three administration schedules being 37 (31–48), 27 (22–42) and 38 (24–49) mmHg
for IN0, IN5 and OUT0, respectively.
Delta TMP was inversely correlated with hemoconcentration (p<0.001, Spearman r = -0.68),
whereas no relation was seen with anti-Xa level or ETP at 240 min (Fig 3).
Other pressures. No significant differences were observed in inlet or outlet line pressures
or in prefilter pressure between the three schedules (S5 Fig).
Fig 2. Endogenous thrombin potential (ETP) in relation to anti-Xa activity.
doi:10.1371/journal.pone.0128634.g002
Fig 3. Delta transmembrane pressure (TMP) in relation to hemoconcentration (BVS), anti-Xa-activity and endogenous thrombin potential (ETP).
Delta TMP is inversely correlated with hemoconcentration (p<0.0001, Spearman r = -0.68), no significant correlation between delta TMP and anti-Xa level or
ETP at 240 min.
doi:10.1371/journal.pone.0128634.g003
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Parameters related to dialysis adequacy
Reduction ratio (RR). RR of urea after 240 min was 77.5 (76.0–81.1), 78.9 (73.8–81.9) and
77.5 (73.6–85.1), with IN0, IN5 and OUT0 respectively, being slightly lower with IN0 compared
to IN5 (p = 0.013). For the other time points no differences were noted between the three
schedules (S1 Table).
RR of beta2microglobulin after 240 min was 82.1 (74.2–84.9), 80.8 (76.5–84.7) and 81.7
(75.9–85.6) with IN0, IN5 and OUT0 respectively. No differences in RR of beta2microglobulin
between the schedules were observed (S1 Table).
Relation between clotting parameters and dialysis efficiency. As illustrated in Fig 4, RR
of urea and beta2microglobulin at 240 min were lower in sessions with an anti-Xa activity at
240 min below 0.3 IU/mL vs. equal or above 0.3 IU/mL: 0.76 (0.69–0.80) vs. 0.84 (0.78–0.86)
and 0.76 (0.74–0.80) vs. 0.85 (0.84–0.88), respectively (p<0.001).
RR of urea and beta2microglobulin were also lower in patients with detectable ETP com-
pared to patients with undetectable ETP at the end of the session: 0.75 (0.69–0.78) vs. 0.83
(0.78–0.86) and 0.76 (0.74–0.79) vs. 0.85 (0.83–0.87), respectively (p<0.001).
Fig 4. Reduction ratio of urea and beta2microglobulin in relation to anti-Xa activity and ETP. Reduction ratio (RR) of urea (unfilled triangles) and
beta2microglobulin (BETA2M) (filled triangles) in sessions with anti-Xa activity above or equal vs. below 0.3 IU/mL and detectable (ETP > 0) vs undetectable
ETP (ETP = 0) at 240 min. Comparison between groups: * p<0.001.
doi:10.1371/journal.pone.0128634.g004
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-No relation was observed between visual clotting score and RR of neither urea nor
beta2microglobulin.
Discussion
In the present study we found that administration of tinzaparin at the inlet blood line before
the start of the session (IN0) resulted in lower anti-Xa activity and higher thrombin generation
compared to administration at the outlet line (OUT0) or administration 5 min after start of the
session (IN5). Anti-Xa levels below 0.3 IU/mL at the end of postdilution hemodiafiltration ses-
sions were associated with more thrombin generation, worse visual clotting score and lower
RR for urea and beta2microglobulin.
Although advised by experts [2, 4, 5], administration at the outlet line is, at least based on
literature data, rarely applied [6, 7]. In most studies LMWHs are injected at the inlet line [8–
20] or the administration site is not specified [21–24]. In the information leaflet of tinzaparin,
enoxaparin and nadroparin, administration via the arterial line is recommended [25], whereas
in guidelines no recommendation concerning the administration site is provided [1].
However, in spite of the currently frequent use of high-flux membranes and hemodiafiltra-
tion, the effect of administration route of LMWHs has, to the best of our knowledge, never
been studied systematically. With low-flux membranes, Vanuytsel et al. found no differences
in anti-Xa activity after administration of nadroparin either at the inlet or outlet line [26].
Tinzaparin has compared to other LMWHs the longest chains. Hence, it is very likely that
when using LMWHs with shorter chains such as enoxaparin and nadroparin, removal will like-
wise occur or even be more pronounced. The removal of enoxaparin during hemodiafiltration
has previously been demonstrated, however without assessing the impact of the administration
site [27].
We ascribe the lower anti-Xa observed in the IN0 schedule, to dialytic/convective removal
of unbound tinzaparin from the rinsing solution through a yet uncoated dialyzer membrane.
Also enhanced adsorption to the uncoated membrane could play a role. Alternatively, the
lower anti-Xa levels with IN0 could simply be the logical consequence of 5 min earlier adminis-
tration compared to the IN5 schedule. A simulation based on kinetic parameters, however re-
sulted in a difference of barely 0.01 IU/mL anti-Xa activity at the end of dialysis with 5 min
difference in administration time, whereas the difference that was observed here was in the
range of 0.1 IU/mL. Hence the role of such small difference in time as applied here is
probably negligible.
In addition to anti-Xa, thrombin generation was assessed by ETP determination. Thrombin
generation assays measure the ability of plasma to generate thrombin following ex vivo activa-
tion of coagulation with tissue factor [28]. Hence, not only the initiation phase, but also the
propagation and terminal phase of clotting are measured; ETP reflects the potential thrombin
forming capacity. As the ultimate goal of anticoagulation during dialysis is the prevention of
clot formation, measurement of ETP is highly informative. We found that anti-Xa activity of
0.3 IU/mL was able to discriminate for measurable ETP. When comparing the different routes
of administration, higher ETP was observed with IN0 compared to IN5 and OUT0.
In healthy controls, ETP was found to be a valuable test for measuring the anticoagulant ef-
fect of heparins [29]. Only limited data on thrombin generation assays in hemodialysis are
available. Predialysis ETP values were found either lower [30] or higher [31] compared to
healthy controls. Vernom et al. found a decreased postdialysis ETP compared to predialysis
values [6]. In contrast to our data, however, they consistently demonstrated thrombin genera-
tion in postdialysis samples. This could be attributed to the lower tinzaparin doses used in their
patients, compared to ours.
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In addition to coagulation parameters, we also evaluated dialysis performance by calculating
the RR of urea and beta2microglobulin. If fibers occlude, it is expected that RR of uremic reten-
tion solutes will be lower. In the present study however, no clinically important differences in
RR were observed between the three administration schedules.
Interestingly, but initially not defined as study outcome, we noticed lower RR of both urea
and beta2microglobulin in sessions ending with an anti-Xa activity below 0.3 IU/mL. Also in
sessions with detectable ETP, a lower RR of these uremic retention solutes was observed. To
the best of our knowledge we are the first to study the anticoagulant effect of LMWH during
hemodiafiltration by measuring RR in relation to anti-Xa and ETP.
No differences in visual clotting score were noted between the three administration sched-
ules. A limitation of the present study is the fact that the investigators rating the visual clotting
score were not blinded to the injection mode.
In conclusion, the injection of tinzaparin, and by extrapolation probably of all LMWHs
with a MW smaller than or equal to that of tinzaparin, at the blood inlet line before the start of
hemodiafiltration is associated with loss of anticoagulant activity. This procedure although
widely applied cannot be recommended as it associated with washing away of expensive medi-
cation. Injection of LMWH at the outlet line or in the inlet line after 5 min are
better alternatives.
In postdilution volume controlled hemodiafiltration, with an exchange volume of 25% of
blood flow and anticoagulated with tinzaparin, an anti-Xa activity below 0.3 IU/mL at the end
of a 4 hour session, is associated with thrombin generation, a higher clotting score and a de-
creased RR of urea and beta2microglobulin. Based on these results, it can be hypothesized that
if tinzaparin dose is targeted to a level slightly above 0.3 IU/mL at the end of the session, not
only improved dialysis efficiency is obtained but in addition overdosing of LMWH will be
avoided. These data need however confirmation from a larger sample sized study in which pa-
tients are injected with various doses of tinzaparin, in order to obtain anti-Xa activity around
0.3 IU/ml at the end of the session.
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